Anti-inflammatory effect of semaglutide: updated systematic review and meta-analysis
Open accessThe DOI matches its Crossref record; 65 of the 66 references it cites were found in a registry or an index.
Abstract
Background: The anti-inflammatory effect could be one of the mechanisms by which semaglutide reduces cardiovascular risk in patients with type 2 diabetes mellitus (T2DM) and/or obesity. Determining the anti-inflammatory effect of semaglutide was the objective of this systematic review and meta-analysis. Methods: This meta-analysis was performed according to the PRISMA guidelines. A literature search was performed to detect randomised clinical trials that have quantified the effect of semaglutide on C-reactive protein (CRP) levels compared to placebo or a control group (other glucose-lowering drugs). The primary outcome was CRP index (final CRP/basal CRP). A random-effects model was used. Results: Thirteen randomised clinical trials were considered eligible ( n = 26,131). Overall, semaglutide therapy was associated with lower CRP index values compared to the placebo group (SMD −0.56; 95% CI −0.69 to −0.43, I 2 92%) or the control group (SMD −0.45; 95% CI −0.68 to −0.23, I 2 82%).Such an association was similarly observed when different treatment regimens (subcutaneous vs. oral) or different populations (patients with or without T2DM) were analysed. The sensitivity analysis showed that the results were robust. Conclusion: The present meta-analysis demonstrated that the use of semaglutide was associated with a reduction in inflammation irrespective of the population evaluated or the treatment regimen used. These findings would explain one of the mechanisms by which semaglutide reduces cardiovascular events. Systematic Review Registration: PROSPERO [CRD42024500551].
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures






Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Clinically, several trials have reported reductions in CRP and related biomarkers with GLP‐1RA therapy [11, 12]”
From Effects of GLP ‐1 Receptor Agonists and Dual GIP / GLP ‐1 Receptor Agonists on Inflammatory and Metabolic Biomarkers in Type 2 Diabetes: A Systematic Review and Meta‐Analysis (2026) · cites this paper as [12]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
1 retracted
Hattori, Y., Jojima, T., Tomizawa, A., Satoh, H., Hattori, S., Kasai, K., & Hayashi, T. (2010) · Diabetologia · doi:10.1007/s00125-010-1831-8 · Cited by 183
RetractedThe PRISMA 2020 statement: An updated guideline for reporting systematic reviews
Page, M. J., McKenzie, J. E., Bossuyt, P. M., Boutron, I., Hoffmann, T. C., Mulrow, C. D., Shamseer, L., Tetzlaff, J. M., Akl, E. A., Brennan, S. E., et al. (2021) · BMJ · doi:10.1136/bmj.n71 · Cited by 108,283
RoB 2: a revised tool for assessing risk of bias in randomised trials
Sterne, J. A. C., Savović, J., Page, M. J., Elbers, R. G., Blencowe, N. S., Boutron, I., Cates, C. J., Cheng, H.-Y., Corbett, M. S., Eldridge, S. M., et al. (2019) · BMJ · doi:10.1136/bmj.l4898 · Cited by 34,787
Conducting Meta-Analyses in R with the metafor Package
Viechtbauer, W. (2010) · Journal of Statistical Software · doi:10.18637/jss.v036.i03 · Cited by 20,464 · cited 1×
“Statistical software R (version 3.5.1) was used for the analysis (23).”
MethodInfluentialWan, X., Wang, W., Liu, J., & Tong, T. (2014) · BMC Medical Research Methodology · doi:10.1186/1471-2288-14-135 · Cited by 11,735 · cited 1×
“The 95% CIs were calculated manually when not reported in the original publications (22).”
MethodSemaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes
Marso, S. P., Bain, S. C., Consoli, A., Eliaschewitz, F. G., Jódar, E., Leiter, L. A., Lingvay, I., Rosenstock, J., Seufert, J., Warren, M. L., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1607141 · Cited by 6,900 · cited 2×
“Accordingly, the anti-in fl ammatory mechanisms associated with GLP-1RA treatment could be closely linked to the cardiovascular bene fi t seen in clinical trials (7, 10).”
BackgroundOnce-Weekly Semaglutide in Adults with Overweight or Obesity
Wilding, J. P. H., Batterham, R. L., Calanna, S., Davies, M., Van Gaal, L. F., Lingvay, I., McGowan, B. M., Rosenstock, J., Tran, M. T. D., Wadden, T. A., et al. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2032183 · Cited by 5,205
C-Reactive Protein, Interleukin 6, and Risk of Developing Type 2 Diabetes Mellitus
Pradhan, A. D. (2001) · JAMA · doi:10.1001/jama.286.3.327 · Cited by 4,433
Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes
Lincoff, A. M., Brown-Frandsen, K., Colhoun, H. M., Deanfield, J., Emerson, S. S., Esbjerg, S., Hardt-Lindberg, S., Hovingh, G. K., Kahn, S. E., Kushner, R. F., et al. (2023) · New England Journal of Medicine · doi:10.1056/nejmoa2307563 · Cited by 3,236 · cited 6×
“Thirteen randomised clinical trials ( n = 26,131 patients) were identi fi ed and considered eligible for this systematic review (10, 24 – 35).”
BackgroundMethodInfluentialC-Reactive Protein Levels and Outcomes after Statin Therapy
Ridker, P. M., Cannon, C. P., Morrow, D., Rifai, N., Rose, L. M., McCabe, C. H., Pfeffer, M. A., & Braunwald, E. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa042378 · Cited by 2,292
Semaglutide in Patients with Heart Failure with Preserved Ejection Fraction and Obesity
Kosiborod, M. N., Abildstrøm, S. Z., Borlaug, B. A., Butler, J., Rasmussen, S., Davies, M., Hovingh, G. K., Kitzman, D. W., Lindegaard, M. L., Møller, D. V., et al. (2023) · New England Journal of Medicine · doi:10.1056/nejmoa2306963 · Cited by 1,669 · cited 4×
“Within the latter, a study speci fi cally including patients with heart failure with preserved ejection fraction is highlighted (35).”
BackgroundMethodInfluential2023 ESC guidelines for the management of cardiovascular disease in patients with diabetes.
Marx, N., Federici, M., Schütt, K., Müller-Wieland, D., Ajjan, R. A., Antunes, M. J., Christodorescu, R. M., Crawford, C., Di Angelantonio, E., Eliasson, B., et al. (2023) · European Heart Journal · doi:10.1093/eurheartj/ehad192 · Cited by 1,642 · cited 1×
“Accordingly, current guidelines recommend the use of GLP-1RAs as fi rst-line antidiabetic therapies in patients at high cardiovascular risk (6).”
BackgroundInflammatory Cytokines and the Risk to Develop Type 2 Diabetes
Spranger, J., Kroke, A., Möhlig, M., Hoffmann, K., Bergmann, M. M., Ristow, M., Boeing, H., & Pfeiffer, A. F. H. (2003) · Diabetes · doi:10.2337/diabetes.52.3.812 · Cited by 1,493
Davies, M., Færch, L., Jeppesen, O. K., Pakseresht, A., Pedersen, S. D., Perreault, L., Rosenstock, J., Shimomura, I., Viljoen, A., Wadden, T. A., et al. (2021) · The Lancet · doi:10.1016/s0140-6736(21)00213-0 · Cited by 1,419
Wadden, T. A., Bailey, T. S., Billings, L. K., Davies, M., Frias, J. P., Koroleva, A., Lingvay, I., O’Neil, P. M., Rubino, D. M., Skovgaard, D., et al. (2021) · JAMA · doi:10.1001/jama.2021.1831 · Cited by 1,114
Ridker, P. M. (2016) · Circulation Research · doi:10.1161/circresaha.115.306656 · Cited by 1,002 · cited 1×
“In clinical practice, CRP values exceeding 3 mg/L are considered as a marker of cardiovascular risk (40, 41).”
BackgroundRubino, D. M., Greenway, F. L., Khalid, U., O’Neil, P. M., Rosenstock, J., Sørrig, R., Wadden, T. A., Wizert, A., Garvey, W. T., STEP 8 Investigators, et al. (2022) · JAMA · doi:10.1001/jama.2021.23619 · Cited by 995
Bempedoic Acid and Cardiovascular Outcomes in Statin-Intolerant Patients
Nissen, S. E., Lincoff, A. M., Brennan, D., Ray, K. K., Mason, D., Kastelein, J. J. P., Thompson, P. D., Libby, P., Cho, L., Plutzky, J., et al. (2023) · New England Journal of Medicine · doi:10.1056/nejmoa2215024 · Cited by 988 · cited 1×
“Statins, colchicine, IL1 β receptor antagonists and bempedoic acid are some examples (42 – 45).”
BackgroundRidker, P. M., MacFadyen, J. G., Everett, B. M., Libby, P., Thuren, T., Glynn, R. J., Ridker, P. M., MacFadyen, J. G., Everett, B. M., Libby, P., et al. (2018) · The Lancet · doi:10.1016/s0140-6736(17)32814-3 · Cited by 919
Two-year effects of semaglutide in adults with overweight or obesity: the STEP 5 trial
Garvey, W. T., Batterham, R. L., Bhatta, M., Buscemi, S., Christensen, L. N., Frias, J. P., Jódar, E., Kandler, K., Rigas, G., Wadden, T. A., et al. (2022) · Nature Medicine · doi:10.1038/s41591-022-02026-4 · Cited by 868
Ridker, P. M., Bhatt, D. L., Pradhan, A. D., Glynn, R. J., MacFadyen, J. G., & Nissen, S. E. (2023) · The Lancet · doi:10.1016/s0140-6736(23)00215-5 · Cited by 672
Ahmann, A. J., Capehorn, M., Charpentier, G., Dotta, F., Henkel, E., Lingvay, I., Holst, A. G., Annett, M. P., & Aroda, V. R. (2018) · Diabetes Care · doi:10.2337/dc17-0417 · Cited by 596
Anti-Inflammatory Effects of GLP-1-Based Therapies beyond Glucose Control
Lee, Y.-S., & Jun, H.-S. (2016) · Mediators of Inflammation · doi:10.1155/2016/3094642 · Cited by 530 · cited 1×
“Strong evidence has shown the anti-in fl ammatory effect of GLP-1RA (16, 17).”
BackgroundRakipovski, G., Rolin, B., Nøhr, J., Klewe, I., Frederiksen, K. S., Augustin, R., Hecksher-Sørensen, J., Ingvorsen, C., Polex-Wolf, J., & Knudsen, L. B. (2018) · JACC: Basic to Translational Science · doi:10.1016/j.jacbts.2018.09.004 · Cited by 509
Type 2 diabetes mellitus: From a metabolic disorder to an inflammatory condition
Hameed, I., Masoodi, S. R., Mir, S. A., Nabi, M., Ghazanfar, K., & Ganai, B. A. (2015) · World Journal of Diabetes · doi:10.4239/wjd.v6.i4.598 · Cited by 506
Aroda, V. R., Rosenstock, J., Terauchi, Y., Altuntas, Y., Lalic, N. M., Morales Villegas, E. C., Jeppesen, O. K., Christiansen, E., Hertz, C. L., Haluzík, M., et al. (2019) · Diabetes Care · doi:10.2337/dc19-0749 · Cited by 493
Rodbard, H. W., Rosenstock, J., Canani, L. H., Deerochanawong, C., Gumprecht, J., Lindberg, S. Ø., Lingvay, I., Søndergaard, A. L., Treppendahl, M. B., Montanya, E., et al. (2019) · Diabetes Care · doi:10.2337/dc19-0883 · Cited by 463
Knop, F. K., Aroda, V. R., do Vale, R. D., Holst-Hansen, T., Laursen, P. N., Rosenstock, J., Rubino, D. M., & Garvey, W. T. (2023) · The Lancet · doi:10.1016/s0140-6736(23)01185-6 · Cited by 431
The NLRP3 inflammasome: Mechanism of action, role in disease and therapies
Wang, L., & Hauenstein, A. V. (2020) · Molecular Aspects of Medicine · doi:10.1016/j.mam.2020.100889 · Cited by 426
Mosenzon, O., Blicher, T. M., Rosenlund, S., Eriksson, J. W., Heller, S., Hels, O. H., Pratley, R., Sathyapalan, T., Desouza, C., Abramof, R., et al. (2019) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(19)30192-5 · Cited by 351
Fujita, H., Morii, T., Fujishima, H., Sato, T., Shimizu, T., Hosoba, M., Tsukiyama, K., Narita, T., Takahashi, T., Drucker, D. J., et al. (2014) · Kidney International · doi:10.1038/ki.2013.427 · Cited by 336
Kadowaki, T., Isendahl, J., Khalid, U., Lee, S. Y., Nishida, T., Ogawa, W., Tobe, K., Yamauchi, T., & Lim, S. (2022) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(22)00008-0 · Cited by 330
Menzel, A., Samouda, H., Dohet, F., Loap, S., Ellulu, M. S., & Bohn, T. (2021) · Antioxidants · doi:10.3390/antiox10030414 · Cited by 217
Bray, J. J. H., Foster‐Davies, H., Salem, A., Hoole, A. L., Obaid, D. R., Halcox, J. P. J., & Stephens, J. W. (2021) · Diabetes Obesity and Metabolism · doi:10.1111/dom.14399 · Cited by 194
Krasner, N. M., Ido, Y., Ruderman, N. B., & Cacicedo, J. M. (2014) · PLoS ONE · doi:10.1371/journal.pone.0097554 · Cited by 186
Avan, A., Tavakoly Sany, S. B., Ghayour‐Mobarhan, M., Rahimi, H. R., Tajfard, M., & Ferns, G. (2018) · Journal of Cellular Physiology · doi:10.1002/jcp.26791 · Cited by 182
Amezcua-Castillo, E., González‐Pacheco, H., Martín, A. S.-S., Méndez-Ocampo, P., Gutiérrez-Moctezuma, I., Massó, F., Sierra‐Lara, D., Springall, R., Rodríguez, E., Arias‐Mendoza, A., et al. (2023) · Biomedicines · doi:10.3390/biomedicines11092444 · Cited by 163
Mouliou, D. S. (2023) · Diseases · doi:10.3390/diseases11040132 · Cited by 160
Seufert, J., & Gallwitz, B. (2014) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.12251 · Cited by 156
Ansari, H. U. H., Qazi, S. U., Sajid, F., Altaf, Z., Ghazanfar, S., Naveed, N., Ashfaq, A. S., Siddiqui, A. H., Iqbal, H., & Qazi, S. (2024) · Endocrine Practice · doi:10.1016/j.eprac.2023.11.007 · Cited by 112
Mosenzon, O., Capehorn, M. S., De Remigis, A., Rasmussen, S., Weimers, P., & Rosenstock, J. (2022) · Cardiovascular Diabetology · doi:10.1186/s12933-022-01585-7 · Cited by 91
NICE’s approach to measuring value
Greaves, F., & Boysen, M. (2021) · BMJ · doi:10.1136/bmj.n7 · Cited by 75
Dulaglutide inhibits high glucose- induced endothelial dysfunction and NLRP3 inflammasome activation
Luo, X., Hu, Y., He, S., Ye, Q., Lv, Z., Liu, J., & Chen, X. (2019) · Archives of Biochemistry and Biophysics · doi:10.1016/j.abb.2019.07.008 · Cited by 74
Sangrós, F. J., Torrecilla, J., Giráldez‐García, C., Carrillo, L., Mancera, J., Mur, T., Franch‐Nadal, J., Díez, J., Goday, A., Serrano, R., et al. (2017) · Revista Española de Cardiología (English Edition) · doi:10.1016/j.rec.2017.04.035 · Cited by 69 · cited 1×
“In addition, obesity is considered a pre-diabetic state (60).”
BackgroundEfficacy and safety of semaglutide for weight management: evidence from the STEP program
Amaro, A., Sugimoto, D., & Wharton, S. (2022) · Postgraduate Medicine · doi:10.1080/00325481.2022.2147326 · Cited by 60
Impact of Glucose-Lowering Medications on Cardiovascular and Metabolic Risk in Type 2 Diabetes
Patti, A. M., Rizvi, A. A., Giglio, R. V., Stoian, A. P., Ligi, D., & Mannello, F. (2020) · Journal of Clinical Medicine · doi:10.3390/jcm9040912 · Cited by 59
Ao, N., Yang, J., Wang, X., & Du, J. (2016) · Hepatology Research · doi:10.1111/hepr.12551 · Cited by 56
Patti, A. M., Nikolic, D., Magan-Fernandez, A., Giglio, R. V., Castellino, G., Chianetta, R., Citarrella, R., Corrado, E., Provenzano, F., Provenzano, V., et al. (2019) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2019.02.006 · Cited by 56
Giglio, R. V., Nikolić, D., Volti, G. L., Stoian, A. P., Banerjee, Y., Magán‐Fernández, A., Castellino, G., Patti, A. M., Chianetta, R., Castracani, C. C., et al. (2020) · Metabolites · doi:10.3390/metabo10100391 · Cited by 55
Novel Therapeutical Approaches to Managing Atherosclerotic Risk
Giglio, R. V., Pantea Stoian, A., Al-Rasadi, K., Banach, M., Patti, A. M., Ciaccio, M., Rizvi, A. A., & Rizzo, M. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22094633 · Cited by 54 · cited 1×
“More importantly, this drug class has been shown to reduce cardiovascular events in patients with type 2 diabetes mellitus (T2DM) at high cardiovascular risk or with established cardiovascular disease (4, 5).”
BackgroundKennedy, C., Hayes, P. C., Salama, S., Hennessy, M., & Fogacci, F. (2023) · Journal of Clinical Medicine · doi:10.3390/jcm12030772 · Cited by 52 · cited 1×
“In summary, alongside its well-established anti-in fl ammatory properties, the impact on weight loss, glycemic control, and reduction of cardiovascular risk factors — such as blood pressure and lipid pro fi le — explains the cardiovascular bene fi ts of semaglutide (62, 63).”
Parab, P. T., Chaudhary, P., Mukhtar, S., Moradi, A., Kodali, A., Okoye, C., Klein, D., Mohamoud, I., Olanisa, O. O., & Hamid, P. (2023) · Cureus · doi:10.7759/cureus.45487 · Cited by 52
Malavazos, A. E., Meregalli, C., Sorrentino, F., Vignati, A., Dubini, C., Scravaglieri, V., Basilico, S., Boniardi, F., Spagnolo, P., Malagoli, P., et al. (2023) · Endocrinology Diabetes and Metabolism Case Reports · doi:10.1530/edm-23-0017 · Cited by 43
Cowart, K. (2020) · Annals of Pharmacotherapy · doi:10.1177/1060028019889064 · Cited by 42
Balogh, D. B., Wagner, L. J., & Fekete, A. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24097789 · Cited by 38 · cited 13×
“Strong evidence has shown the anti-in fl ammatory effect of GLP-1RA (16, 17).”
BackgroundInfluentialPatti, A. M., Giglio, R. V., Allotta, A., Bruno, A., Bella, T. D., Stoian, A. P., Ciaccio, M., & Rizzo, M. (2023) · Biomedicines · doi:10.3390/biomedicines11051362 · Cited by 36
Chen, T., Liu, G., & Yu, B. (2023) · Clinical Research in Cardiology · doi:10.1007/s00392-023-02254-9 · Cited by 24
Pharmacokinetics and Clinical Implications of Oral Semaglutide for Type 2 Diabetes Mellitus
Clements, J. N., Isaacs, D. M., Hartman, R. E., & Gambill, K. (2020) · Clinical Pharmacokinetics · doi:10.1007/s40262-020-00951-6 · Cited by 22
C-REACTIVE PROTEIN AND CARDIOVASCULAR DISEASE IN PEOPLE WITH DIABETES
Xu, Y., & Whitmer, K. R. (2006) · AJN American Journal of Nursing · doi:10.1097/00000446-200608000-00027 · Cited by 21
Potential New Therapeutic Implications of Semaglutide: New Colours of the Rainbow?
Gouveri, E., Popovic, D. S., & Παπάνας, Ν. (2023) · Diabetes Therapy · doi:10.1007/s13300-023-01506-1 · Cited by 16
Practical guidance for use of oral semaglutide in primary care: a narrative review
Morales, J., Shubrook, J. H., & Skolnik, N. (2020) · Postgraduate Medicine · doi:10.1080/00325481.2020.1788340 · Cited by 14 · cited 1×
“…adipose tissue and improvement of cardiac contractility), vascular (vasodilator effect and improvement of endothelial dysfunction), renal (reduced glomerular fi ltration rate and proteinuria drop) and metabolic (blood pressure decreased, lipid pro fi le improved and glucose-lowering effect) (11).”
BackgroundBoczar, K. E., & Beanlands, R. S. (2022) · Canadian Journal of Cardiology · doi:10.1016/j.cjca.2022.05.023 · Cited by 10
Guo, X., Sang, C., Tang, R., Jiang, C., Li, S., Liu, N., Long, D., Du, X., Dong, J., & Ma, C. (2023) · Diabetes Obesity and Metabolism · doi:10.1111/dom.15043 · Cited by 10
Jódar, E. (2014) · Medicina Clínica · doi:10.1016/s0025-7753(14)70103-4 · Cited by 3 · cited 1×
“It would thus appear that the molecular, pharmacokinetic and pharmacodynamic differences in these drugs could in fl uence the anti-in fl ammatory effect (61).”
BackgroundTwo-year Effect of Semaglutide 2.4 mg on Control of Eating in Adults with Overweight/Obesity: STEP 5
Wharton, S., Batterham, R. L., Bhatta, M., Buscemi, S., Christensen, L., Frias, J., Jódar, E., Kandler, K., Rigas, G., Wadden, T., et al. (2021) · UCL Discovery (University College London) · Cited by 1
Research works printed but not linked: 1
- White-Flowers, 2010, Obesity as an inflammatory process, Bol Med Hosp Infant Mex, 67, 88
Cited by
Cummings, J. L., Atri, A., Sano, M., Zetterberg, H., Scheltens, P., Knop, F. K., Johannsen, P., Wichmann, C. A., Abschneider, R. M., Leon, T., et al. (2026) · The Lancet · doi:10.1016/s0140-6736(26)00459-9 · Cited by 110
Trends in Glucagon-Like Peptide 1 Receptor Agonist Prescribing Patterns
(2025) · The American Journal of Managed Care · doi:10.37765/ajmc.2025.89778 · Cited by 65
Cesaro, A., Pastori, D., Acerbo, V., Biccirè, F. G., Golino, M., Panico, D., Prati, F., Abbate, A., Lip, G. Y. H., & Calabrò, P. (2025) · European Journal of Preventive Cardiology · doi:10.1093/eurjpc/zwaf257 · Cited by 56
Ngabea, M. A., & Dimeji, I. Y. (2025) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2025.152822 · Cited by 35
Bailey, C. J., Flatt, P. R., & Conlon, J. M. (2025) · Peptides · doi:10.1016/j.peptides.2025.171380 · Cited by 40
“…studies have observed a decrease in pro-inflammatory markers during use of a GLP-1RA, and an anti-inflammatory effect has been considered to contribute to the pleiotropic properties of these agents across metabolic, cardiorenal, neuro-degenerative, osteoarthritic and other diseases [47,68,69].”
Metadata
- Authors
- Masson, W., Lobo, M., Nogueira, J. P., Rodriguez-Granillo, A. M., Barbagelata, L. E., & Siniawski, D.
- Affiliations
- Hospital Italiano de Buenos Aires (AR)
- Universidad Internacional de las Américas (CR)
- Sanatorio Otamendi y Miroli (AR)
- Corresponding author
- Masson, Walter
- ORCID
- Venue
- Frontiers in Cardiovascular Medicine
- Publisher
- Frontiers Media SA
- Published
- 2024-07-05
- Volume
- 11
- Pages
- 1379189-1379189
- ISSN
- 2297-055X (ISSN-L)
- PMC
- PMC11270812
- OpenAlex
- W4400369011
- Cited by
- 57
- References
- 66
- Citations by year
- 2026: 29 · 2025: 27 · 2024: 1
- FWCI
- 3.35
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- Locations
- Frontiers in Cardiovascular Medicine (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Adipokines, Inflammation, and Metabolic Diseases
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes, Cardiovascular Risks, and Lipoproteins
- Keywords
- semaglutide, anti-inflammatory activity, C-reactive protein, type 2 diabetes, obesity, cardiovascular risk reduction, GLP-1 receptor agonists, inflammation
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.